Skip to main content

T1DM clinical trials at UCSF
1 in progress, 1 open to new patients

  • Tocilizumab (TCZ) in New-onset Type 1 Diabetes

    open to eligible people ages 6–17

    Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study doctors think that giving medicines to affect the immune system soon after diabetes is diagnosed may stop, delay or decrease the destruction of beta cells, resulting in better glucose control. Researchers believe that tocilizumab could have some effect on the cells in the immune system that are thought to be involved in the development of type 1 diabetes. This study will test whether tocilizumab can help preserve or delay destruction of remaining beta cells in people recently diagnosed type 1 diabetes.

    San Francisco, California and other locations